Impact of device-aided therapies on quality of life in patients with Parkinson's disease. A comparative multicenter observational study.
Impact of device-aided therapies on quality of life in patients with Parkinson's disease. A comparative multicenter observational study.
Where did the research take place?
Possible study sites were matched from the text; these need review.
ES · Possible study site · country only
6 M) were collected from a descriptive, observational, prospective, multicenter, clinical registry conducted in Spain entitled DATs-PD GETM Spanish Registry.Location evidence
A Coruña, ES · Author affiliation
CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. diegosangar@yahoo.es.Location evidence
Móstoles, ES · Author affiliation
Hospital Universitario de Móstoles, Madrid, Spain.Location evidence
Madrid, ES · Author affiliation
Hospital Universitario de Móstoles, Madrid, Spain.Location evidence
Sevilla, ES · Author affiliation
Servicio de Neurología y Neurofisiología Clínica, Unidad de Trastornos del Movimiento, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.Location evidence
Universidad, ES · Author affiliation
Servicio de Neurología y Neurofisiología Clínica, Unidad de Trastornos del Movimiento, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.Location evidence
Centro, ES · Author affiliation
CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.Location evidence
Toledo, ES · Author affiliation
Hospital Universitario de Toledo, Toledo, Spain.Location evidence
Palma, ES · Author affiliation
Hospital Universitario Son Espases, Palma, Spain.Location evidence
Candelaria, ES · Author affiliation
Hospital Universitario de La Candelaria, Santa Cruz de Tenerife, Spain.Location evidence
Santa Cruz de Tenerife, ES · Author affiliation
Hospital Universitario de La Candelaria, Santa Cruz de Tenerife, Spain.Location evidence
Sant Joan Despí, ES · Author affiliation
Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain.Location evidence
Barcelona, ES · Author affiliation
Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain.Location evidence
Pontevedra, ES · Author affiliation
Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.Location evidence
Oviedo, ES · Author affiliation
Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Device aided-therapies (DATs) improve health-related quality of life (HRQoL) in people with Parkinson's disease (PwP). However, no studies comparing all DATs have been conducted to date. Our aim was to compare the effect of different DATs on HRQoL and other disease-related variables in PwP. Data from baseline (V1) and the 6-month follow-up visit (V3.6 M) were collected from a descriptive, observational, prospective, multicenter, clinical registry conducted in Spain entitled DATs-PD GETM Spanish Registry. The primary endpoint was the change from V1 to V3.6 M in the 39-item Parkinson's Disease Questionnaire (PDQ-39) total score. Relative change (RC) and Cohen's d (d) effect were applied. The effect over many other variables was also analyzed. HRQoL improved significantly in the entire cohort (N = 137) with a moderate decrease of 13.4% in the PDQ-39 total score (from 58.9 ± 22.9 at V1 to 51.0 ± 26.8 at V3.6 M; d = 0.51; p < 0.0001). No differences in the change of the PDQ-39 total score were detected between both subcutaneous therapies (i.e., foslevodopa/foscarbidopa [fLD/fCD] and continuous subcutaneous apomorphine infusion [CSAI]; p = 0.666) and between subcutaneous and enteral therapies (p = 0.721). Although a greater improvement in HRQoL was observed in PwP treated with deep brain stimulation (DBS) (N = 30; RC = -26.3%; d = 0.83; p = 0.002) compared to those who received a pump system (N = 107; RC = -10.2%; d = 0.41; p = 0.003) (p = 0.009), the effect was not significant after adjustment for age, sex, and disease duration (p = 0.161). Off time, dyskinesia, motor symptoms, and non-motor symptoms improved significantly in the entire cohort. HRQoL improved in PwP after being treated with a DAT.